vs
BioCardia, Inc.（BCDA）与Cardio Diagnostics Holdings, Inc.（CDIO）财务数据对比。点击上方公司名可切换其他公司
BioCardia是一家临床阶段生物技术公司，专注于心血管疾病再生疗法研发，核心产品包括针对心力衰竭、心肌梗死等病症的细胞和基因疗法候选管线，主要面向北美及全球心脏病诊疗市场，致力于改善心脏病患者的长期心脏功能。
Cardio Diagnostics Holdings, Inc.是一家专注于精准心血管医疗的企业，开发并商业化整合遗传与表观遗传技术的诊断检测产品，可早期识别冠心病、心力衰竭等心血管疾病，主要服务美国市场的医疗机构、临床实验室与患者。
BCDA vs CDIO — 直观对比
营收规模更大
CDIO
是对方的Infinity倍
$0
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $0 | $3.6K |
| 净利润 | $-2.0M | — |
| 毛利率 | — | — |
| 营业利润率 | — | — |
| 净利率 | — | — |
| 营收同比 | — | -21.2% |
| 净利润同比 | 13.6% | 3.6% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCDACDIO
| Q4 25 | $0 | $3.6K | ||
| Q3 25 | $0 | $2.9K | ||
| Q2 25 | $0 | $7.5K | ||
| Q1 25 | $0 | — | ||
| Q4 24 | $0 | $4.5K | ||
| Q3 24 | $0 | $6.6K | ||
| Q2 24 | $3.0K | $7.9K | ||
| Q1 24 | $55.0K | $15.9K |
净利润BCDACDIO
| Q4 25 | $-2.0M | — | ||
| Q3 25 | $-1.5M | $-1.7M | ||
| Q2 25 | $-2.0M | $-1.7M | ||
| Q1 25 | $-2.7M | — | ||
| Q4 24 | $-2.3M | — | ||
| Q3 24 | $-1.7M | $-1.4M | ||
| Q2 24 | $-1.6M | $-1.3M | ||
| Q1 24 | $-2.3M | $-4.2M |
营业利润率BCDACDIO
| Q4 25 | — | — | ||
| Q3 25 | — | -59950.9% | ||
| Q2 25 | — | -22457.5% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -21412.9% | ||
| Q2 24 | -54966.7% | -16295.6% | ||
| Q1 24 | -4136.4% | -26105.3% |
净利率BCDACDIO
| Q4 25 | — | — | ||
| Q3 25 | — | -60053.8% | ||
| Q2 25 | — | -22517.7% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -21467.6% | ||
| Q2 24 | -54866.7% | -16365.9% | ||
| Q1 24 | -4121.8% | -26140.0% |
每股收益（稀释后）BCDACDIO
| Q4 25 | — | — | ||
| Q3 25 | — | $-0.98 | ||
| Q2 25 | — | $-0.97 | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-1.73 | ||
| Q2 24 | — | $-1.71 | ||
| Q1 24 | — | $-5.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.5M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $895.0K | $7.0M |
| 总资产 | $3.4M | $7.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCDACDIO
| Q4 25 | $2.5M | — | ||
| Q3 25 | $5.3M | — | ||
| Q2 25 | $980.0K | — | ||
| Q1 25 | $949.0K | — | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | $4.9M | — | ||
| Q2 24 | $1.4M | — | ||
| Q1 24 | $949.0K | — |
股东权益BCDACDIO
| Q4 25 | $895.0K | $7.0M | ||
| Q3 25 | $2.6M | $8.2M | ||
| Q2 25 | $-1.9M | $9.7M | ||
| Q1 25 | $-1.5M | — | ||
| Q4 24 | $837.0K | $9.6M | ||
| Q3 24 | $2.8M | $3.7M | ||
| Q2 24 | $-2.0M | $3.1M | ||
| Q1 24 | $-2.3M | $3.0M |
总资产BCDACDIO
| Q4 25 | $3.4M | $7.8M | ||
| Q3 25 | $6.1M | $8.8M | ||
| Q2 25 | $2.1M | $10.4M | ||
| Q1 25 | $2.2M | — | ||
| Q4 24 | $3.7M | $10.6M | ||
| Q3 24 | $6.3M | $4.5M | ||
| Q2 24 | $2.9M | $4.0M | ||
| Q1 24 | $2.7M | $4.3M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.5M | $-5.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-5.9M |
| 自由现金流率自由现金流/营收 | — | -166361.5% |
| 资本支出强度资本支出/营收 | — | 5269.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-14.3M |
8季度趋势，按日历期对齐
经营现金流BCDACDIO
| Q4 25 | $-2.5M | $-5.7M | ||
| Q3 25 | $-1.7M | $-1.4M | ||
| Q2 25 | $-1.6M | $-1.6M | ||
| Q1 25 | $-1.6M | — | ||
| Q4 24 | $-2.4M | $-5.0M | ||
| Q3 24 | $-2.6M | $-1.2M | ||
| Q2 24 | $-1.3M | $-1.2M | ||
| Q1 24 | $-1.5M | $-1.2M |
自由现金流BCDACDIO
| Q4 25 | — | $-5.9M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-1.6M | ||
| Q1 25 | — | — | ||
| Q4 24 | $-2.4M | $-5.2M | ||
| Q3 24 | $-2.6M | $-1.2M | ||
| Q2 24 | $-1.3M | $-1.4M | ||
| Q1 24 | — | $-1.3M |
自由现金流率BCDACDIO
| Q4 25 | — | -166361.5% | ||
| Q3 25 | — | -54509.7% | ||
| Q2 25 | — | -21273.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -115422.6% | ||
| Q3 24 | — | -17942.3% | ||
| Q2 24 | -43833.3% | -17513.3% | ||
| Q1 24 | — | -7866.9% |
资本支出强度BCDACDIO
| Q4 25 | — | 5269.1% | ||
| Q3 25 | — | 5703.5% | ||
| Q2 25 | — | 250.1% | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4759.9% | ||
| Q3 24 | — | 353.3% | ||
| Q2 24 | 100.0% | 2133.4% | ||
| Q1 24 | 0.0% | 125.5% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
